These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36035359)

  • 1. Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses.
    Liu Y; Park D; Cafiero TR; Bram Y; Chandar V; Tseng A; Gertje HP; Crossland NA; Su L; Schwartz RE; Ploss A
    JHEP Rep; 2022 Sep; 4(9):100535. PubMed ID: 36035359
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Tu T; Zehnder B; Qu B; Urban S
    JHEP Rep; 2021 Feb; 3(1):100195. PubMed ID: 33385130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infection courses, virological features and IFN-α responses of HBV genotypes in cell culture and animal models.
    Zhang M; Zhang Z; Imamura M; Osawa M; Teraoka Y; Piotrowski J; Ishida Y; Sozzi V; Revill PA; Saito T; Chayama K; Liang TJ
    J Hepatol; 2021 Dec; 75(6):1335-1345. PubMed ID: 34363922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed.
    Lai CL; Wong DK; Wong GT; Seto WK; Fung J; Yuen MF
    JHEP Rep; 2020 Jun; 2(3):100112. PubMed ID: 32462119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype.
    Shen F; Li Y; Wang Y; Sozzi V; Revill PA; Liu J; Gao L; Yang G; Lu M; Sutter K; Dittmer U; Chen J; Yuan Z
    Hepatology; 2018 Apr; 67(4):1237-1252. PubMed ID: 29059468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new high-content screening assay of the entire hepatitis B virus life cycle identifies novel antivirals.
    Yang J; König A; Park S; Jo E; Sung PS; Yoon SK; Zusinaite E; Kainov D; Shum D; Windisch MP
    JHEP Rep; 2021 Aug; 3(4):100296. PubMed ID: 34222850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
    Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
    J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.
    Arora A; Singh SP; Kumar A; Saraswat VA; Aggarwal R; Bangar M; Bhaumik P; Devarbhavi H; Dhiman RK; Dixit VK; Goel A; Goswami B; Kapoor D; Madan K; Narayan J; Nijhawan S; Pandey G; Rai RR; Sahu MK; Saraf N; Shalimar ; Shenoy T; Thomas V; Wadhawan M;
    J Clin Exp Hepatol; 2018 Mar; 8(1):58-80. PubMed ID: 29743798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregenomic RNA Launch Hepatitis B Virus Replication System Facilitates the Mechanistic Study of Antiviral Agents and Drug-Resistant Variants on Covalently Closed Circular DNA Synthesis.
    Zhao Q; Chang J; Rijnbrand R; Lam AM; Sofia MJ; Cuconati A; Guo JT
    J Virol; 2022 Dec; 96(24):e0115022. PubMed ID: 36448800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.
    Khatun M; Kumar K; Baidya A; Mondal RK; Baszczyňski O; Kalčic F; Banerjee S; Dhali GK; Das K; Chowdhury A; Janeba Z; Chakrabarti S; Datta S
    J Virol; 2022 Jan; 96(2):e0180021. PubMed ID: 34730399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
    Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
    World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
    Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
    J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
    García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
    J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of infectious hepatitis B virus particles by an end-point dilution assay identifies a novel class of inhibitors.
    Jo E; Kim H; König A; Yang J; Yoon SK; Windisch MP
    Antiviral Res; 2021 Dec; 196():105195. PubMed ID: 34736995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells.
    Aggarwal A; Odorizzi PM; Brodbeck J; van Buuren N; Moon C; Chang S; Adona M; Suthram S; Suri V; Trowe T; Turner S; Marcellin P; Buti M; Gaggar A; Fletcher SP; Diehl L; Feierbach B; Balsitis S
    JHEP Rep; 2023 Apr; 5(4):100664. PubMed ID: 36908748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro.
    Salpini R; Surdo M; Cortese MF; Palumbo GA; Carioti L; Cappiello G; Spanò A; Trimoulet P; Fleury H; Vecchiet J; Pasquazzi C; Mirabelli C; Scutari R; Sacco A; Alkhatib M; Missale G; Francioso S; Sarmati L; Andreoni M; Angelico M; Ceccherini-Silberstein F; Levrero M; Perno CF; Belloni L; Svicher V
    Clin Microbiol Infect; 2019 Jul; 25(7):906.e1-906.e7. PubMed ID: 30472417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBVcircle: A novel tool to investigate hepatitis B virus covalently closed circular DNA.
    Yan Z; Zeng J; Yu Y; Xiang K; Hu H; Zhou X; Gu L; Wang L; Zhao J; Young JAT; Gao L
    J Hepatol; 2017 Jun; 66(6):1149-1157. PubMed ID: 28213165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.
    König A; Yang J; Jo E; Park KHP; Kim H; Than TT; Song X; Qi X; Dai X; Park S; Shum D; Ryu WS; Kim JH; Yoon SK; Park JY; Ahn SH; Han KH; Gerlich WH; Windisch MP
    J Hepatol; 2019 Aug; 71(2):289-300. PubMed ID: 31077792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct distribution pattern of hepatitis B virus genotype C and D in liver tissue and serum of dual genotype infected liver cirrhosis and hepatocellular carcinoma patients.
    Datta S; Roychoudhury S; Ghosh A; Dasgupta D; Ghosh A; Chakraborty BC; Ray S; Gupta S; Santra AK; Datta S; Das K; Dhali GK; Chowdhury A; Banerjee S
    PLoS One; 2014; 9(7):e102573. PubMed ID: 25032957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.